Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 8/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.57 |
| ▸ | PIM1 | P11309 | 4/20 | 0.57 |
| ▸ | PRKACA | P17612 | 4/20 | 0.57 |
| ▸ | CDK2 | P24941 | 4/20 | 0.57 |
| ▸ | GSK3B | P49841 | 4/20 | 0.57 |
| ▸ | HIPK2 | Q9H2X6 | 4/20 | 0.57 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.51 |
| ▸ | JAK3 | P52333 | 3/20 | 0.51 |
| ▸ | PLK4 | O00444 | 2/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | CSF1R | P07333 | 2/20 | 0.51 |
| ▸ | RET | P07949 | 2/20 | 0.51 |
| ▸ | TYK2 | P29597 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30576680 | 1.00 | CDC7 (0.61) | CDC7ROCK2PIM1PRKACACDK2 | |
| SCHEMBL858614 | 0.86 | CAMKK2 (0.56) | CDC7ROCK2PIM1PRKACACDK2 | |
| SCHEMBL857907 | 0.84 | CDC7 (0.61) | CDC7ROCK2PIM1PRKACACDK2 | |
| SCHEMBL1718139 | 0.83 | AURKB (0.62) | PRKACACLK4MAP4K4DYRK1AFGFR1 | |
| SCHEMBL8941196 | 0.82 | JAK2 (0.67) | JAK2NTRK1KIT | |
| SCHEMBL857087 | 0.81 | CDC7 (0.64) | CDC7ROCK2PIM1PRKACACDK2 | |
| SCHEMBL18418494 | 0.80 | CDC7 (0.71) | CDC7ROCK2PIM1PRKACACDK2 | |
| SCHEMBL12928781 | 0.80 | CDC7 (0.57) | CDC7ROCK2PIM1PRKACACDK2 | |
| SCHEMBL858205 | 0.79 | BRD4 (0.62) | CDC7ROCK2PIM1PRKACACDK2 | |
| SCHEMBL5823539 | 0.78 | DYRK1A (0.53) | CDC7ROCK2PIM1PRKACACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240318141-A1 | MATURATION AGENT | Orizuru Therapeutics, Inc. (JP) | 2024-09-26 | — | — | US | disclosed |
| WO-2024071010-A1 | T CELL PRODUCTION METHOD | 国立大学法人京都大学 | 2024-04-04 | — | — | WO | disclosed |
| EP-4293105-A1 | MATURATION AGENT | Orizuru Therapeutics, Inc. (JP) | 2023-12-20 | — | — | EP | disclosed |
| US-20230399607-A1 | MATURATION AGENT | Orizuru Therapeutics, Inc. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230399607-A1 | MATURATION AGENT | Orizuru Therapeutics, Inc. (JP) | 2023-12-14 | — | — | US | disclosed |
| CN-116829697-A | Ripening agent | 千纸鹤治疗公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023182328-A1 | METHOD FOR PRODUCING REGULATORY T CELLS | 国立大学法人京都大学 | 2023-09-28 | — | — | WO | disclosed |
| WO-2022172960-A1 | MATURATION AGENT | オリヅルセラピューティクス株式会社 | 2022-08-18 | — | — | WO | disclosed |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| EP-1730146-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095400-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | CDC7 274/4885ROCK2 241/4885PIM1 412/4885 |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | CDC7 274/4885ROCK2 241/4885PIM1 412/4885 |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | LCK, PDXK, CHUK | CDC7 864/4885ROCK2 469/4885PIM1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.